APA

Mir M. D. A., Chaudhary S., Payasi A., Sood R., Mavuduru R. S. & Shameem M. (2019). CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. : Open forum infectious diseases.

Chicago

Mir M D Amin, Chaudhary Saransh, Payasi Anurag, Sood Rajeev, Mavuduru Ravimohan S and Shameem Mohd. 2019. CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. : Open forum infectious diseases.

Harvard

Mir M. D. A., Chaudhary S., Payasi A., Sood R., Mavuduru R. S. and Shameem M. (2019). CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. : Open forum infectious diseases.

MLA

Mir M D Amin, Chaudhary Saransh, Payasi Anurag, Sood Rajeev, Mavuduru Ravimohan S and Shameem Mohd. CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. : Open forum infectious diseases. 2019.